- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.08. | Kairos Pharma to conduct 1-for-7 reverse stock split | 1 | Investing.com | ||
| 21.08. | Kairos Pharma announces 1-for-7 reverse stock split to maintain NYSE compliance | 2 | Seeking Alpha | ||
| 21.08. | Kairos Pharma kündigt Aktienzusammenlegung im Verhältnis 1 zu 7 an | 1 | Investing.com Deutsch | ||
| 21.08. | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.08. | Kairos Pharma Announces 1-for-7 Reverse Stock Split | 161 | Business Wire | LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct... ► Artikel lesen | |
| 12.08. | Kairos Pharma, LTD. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 24.07. | Kairos Pharma Announces Strategic Collaboration With Bayer To Enhance XOFIGO Activity In Metastatic Prostate Cancer | 34 | pulse2.com | ||
| KAIROS PHARMA Aktie jetzt für 0€ handeln | |||||
| 22.07. | Bayer, Kairos Pharma Collaborate to Boost Xofigo Effectiveness in Metastatic Prostate Cancer | 48 | Contract Pharma | ||
| 22.07. | Kairos Pharma partners with Bayer on prostate cancer study | 53 | Investing.com | ||
| 22.07. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | Kairos Pharma (KAPA) Stock Surges Over 22% After Hours: Why is it Moving? | 1 | Benzinga.com | ||
| 15.07. | CEO.CA Technologies Ltd.: CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever | 439 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining... ► Artikel lesen | |
| 15.07. | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.06. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.06. | Kairos Pharma signs term sheet to acquire lung cancer asset | 3 | Investing.com | ||
| 04.06. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.05. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Kairos Pharma, LTD. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | LD Micro: Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI | 560 | Newsfile | Los Angeles, California--(Newsfile Corp. - May 13, 2026) - Kairos Pharma, Ltd. (NYSE American: KAPA) announced today that it will be participating in the 16th Annual LD Micro Invitational at the... ► Artikel lesen | |
| 08.05. | Kairos Pharma: Interview With Chairman & CEO Dr. John Yu About The Biopharmaceutical Company | 1 | pulse2.com |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,070 | -3,60 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INFLARX | 1,950 | +1,99 % | InflaRx: Revolutionäre Therapieansätze könnten alles verändern | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| IBIO | 1,163 | 0,00 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| GERON | 1,317 | +1,35 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| IMMUNITYBIO | 6,880 | -1,01 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 8,260 | +1,29 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 2,727 | +0,44 % | Myriad Genetics, Inc.: Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability | Highlights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is... ► Artikel lesen | |
| MANNKIND | 3,395 | 0,00 % | MannKind-Aktie: Biotech-Chance mit neuen Wachstumstreibern | Die MannKind-Aktie steht nach zwei wichtigen FDA-Zulassungen vor einer neuen Wachstumsphase. Bei einer Marktkapitalisierung von rund 1,24 Milliarden US-Dollar könnte der Markt das langfristige Potenzial... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,064 | +0,66 % | Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab | Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business
BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo... ► Artikel lesen | |
| IMMUNIC | 13,485 | -2,56 % | EQS-News: Immunic AG: Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Issuer: Immunic AG
/ Key word(s): Quarter Results
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
11.08.2026 / 12:30 CET/CEST
The... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 6,910 | -0,29 % | TD Cowen raises Iovance Biotherapeutics price target on sales outlook | ||
| MOLECULIN BIOTECH | 0,640 | 0,00 % | Moleculin Biotech, Inc.: Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial | Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AMLMIRACLE trial advancing toward planned 90-patient enrollment milestone in September... ► Artikel lesen | |
| GENPREX | 3,700 | +0,82 % | Genprex, Inc.: Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy | Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials
AUSTIN, Texas, Aug. 18, 2026... ► Artikel lesen | |
| MESOBLAST | 1,560 | +2,33 % | Eli Lilly zahlt bis zu 7 Milliarden für Zelltherapie - warum jetzt auch bei Mesoblast der nächste große Test beginnt |
KAIROS PHARMA LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,236 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KAIROS PHARMA LTD finden Sie auf Wallstreet Online.